Healthcare & Biotech
Sensible Biotechnologies
Unlocking the next generation of mRNA medicines
The future of mRNA therapeutics is hampered by manufacturing challenges and unless solved, its exciting potential may never be realised. Sensible enables the next generation of mRNA medicines by turning living cells into factories producing abundant, highly stable and non-immunogenic mRNA in a scalable and cost-effective way.
- Therapeutics
- Synthetic Biology
- Biotech
- Website
- sensible.bio
- Headquarters
- Oxford, England, United Kingdom
- Team size
- 51-200 people
- Founded
- 2021
- Demo
- 20 min demo
Similar companies
Velorum TherapeuticsBreakthrough medicines unlocking the biology of heme
ParcelBioElevated mRNA for transformative medicines.
ACXNext-generation biocides for sustainable agriculture at scale
Ansa BiotechnologiesNext-generation DNA synthesis using enzymes
Ochre BioRNA medicines for liver diseases
Ohmic BiosciencesGenetically engineering plants for disease resistance.
Eris BiotechOur drugs engage the immune system to fight tumors
EpinomaWe engineer proteins that control the operating system of biology.